Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 26, 2007 Brian Orelli	Second-Line Isn't Second Best Schering-Plough gets a positive recommendation for its hepatitis C drugs as a second-line treatment in Europe.
Chemistry World September 11, 2013 Phillip Broadwith	First biosimilar antibody drugs approved in Europe The European commission has given final marketing approval to the first generic versions of monoclonal antibody drug infliximab (Johnson & Johnson's Remicade).
The Motley Fool April 11, 2011 Brian Orelli	Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected.
The Motley Fool August 27, 2008 Brian Orelli	Teva Tells It Like It Is For Teva Pharmaceuticals, the details only confirmed the great initial report of the clinical trial success for its Parkinson's disease treatment Azilect.
The Motley Fool September 14, 2006 Brian Lawler	Close Failure for Genzyme Will Genzyme's Campath get approval? Investors shouldn't hold their breath.
Chemistry World August 2, 2007 Victoria Gill	Europe Poised for a Surge in Generic Drugs The European Medicines Agency's Committee for Medicinal Products for Human use has recommended the approval of a schizophrenia treatment which is the first generic drug to be assessed under Europe's centralized procedure.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
Chemistry World July 2, 2013 Phillip Broadwith	Biosimilar drugs step up complexity The first ever generic monoclonal antibody therapies have been recommended for approval in Europe.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
The Motley Fool September 25, 2007 Brian Orelli	Onyx Moves Ahead Bayer and Onyx score a positive recommendation from an EU committee, moving one step closer to being able to market their cancer-fighting drug Nexavar in Europe.
The Motley Fool June 18, 2008 Brian Lawler	Elan's and Wyeth's Data: Success or Failure? Elan and partner Wyeth released new mid-stage data for their potential blockbuster bapineuzumab (AAB-001) for Alzheimer's disease, but the results aren't conclusive.
American Family Physician December 15, 2006	Parkinson's Disease: What You Should Know What is Parkinson's disease?... How can I tell if I have Parkinson's disease?... How will my doctor know if I have it?... How is Parkinson's disease treated?... etc.
AskMen.com Jacob Franek	Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon.
Chemistry World July 3, 2014 Maria Burke	Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK.
American Family Physician December 15, 2006 Rao et al.	Parkinson's Disease: Diagnosis and Treatment Family physicians should have a good understanding of Parkinson's disease because of its increasing prevalence as the population ages. Treatment should be individualized to decrease symptoms while minimizing motor and nonmotor complications.
The Motley Fool May 22, 2007 Brian Lawler	Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing.
The Motley Fool December 19, 2008 Brian Orelli	Eli Lilly's Good News Misses the Mark EU approval of its blood thinner is nice, but U.S. approval is what will really matter.
The Motley Fool June 28, 2004 Alyce Lomax	Is Amgen's Engine Stalled? Amgen slipped in today's trading session after it said that an experimental drug for advanced cases of Parkinson's disease didn't meet its primary end point in a recent clinical trial.
The Motley Fool November 26, 2007 Brian Lawler	Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note.
Managed Care September 2005 Thomas Morrow	Dual-Treatment Approach to Parkinson's Disease The treatment of Parkinson's disease is complicated. Patients may benefit from a dual approach that uses medical therapy with new innovative treatment systems.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool October 26, 2004 Charly Travers	Biotech's 5-Baggers: Part 2 Several hot drugs are generating smoking returns. If the goal for an investor is to aim for one of these five-baggers, then one option is to invest before the company passes through the inflection point.
The Motley Fool June 29, 2010 Brian Orelli	The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting.
The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade.
The Motley Fool May 28, 2010 Brian Orelli	Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree.
The Motley Fool August 28, 2006 Brian Lawler	The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
The Motley Fool August 16, 2005 Karl Thiel	New Life for Boston Life Sciences? The biotech's stock soars on news of potential approval of its imaging agent for Parkinson's and ADHD. Enthusiastic retail investors drove this week's huge move on the market, and those are the only folks who will be moving the stock for some time to come.
The Motley Fool September 23, 2010 Brian Orelli	Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease.
Pharmaceutical Executive November 1, 2012	Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes.
The Motley Fool April 27, 2011 Arundhati Parmar	Medtronic and Eli Lilly Join Hands to Combat Parkinson's Disease The partnership aims to research and develop a new approach to treating the debilitating disease.
Chemistry World October 2, 2007 Jonathan Edwards	Light Shed on Parkinson's Culprit European scientists have developed a new technique to detect attogram quantities of iron in living cells -- providing further evidence of the role the metal plays in Parkinson's disease.
Managed Care June 2006 Thomas Morrow	Pompe Disease Therapy Presents Coverage Challenge Although Myozyme is approved for the infantile form of Pompe disease, it is logical to extend coverage to patients with the late onset form.
The Motley Fool March 4, 2011 Brian Orelli	Up 15% for That? InterMune investors react to a non-event.
The Motley Fool June 10, 2011 Brian Orelli	Abbott Picks Pumps Over Pills Treat Parkinson's disease, medical-device style.
AskMen.com Jacob Franek	Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
American Family Physician October 1, 2003 Vincent W. Delagarza	Pharmacologic Treatment of Alzheimer's Disease: An Update Alzheimer's disease is characterized by the development of senile plaques and neurofibrillary tangles, which are associated with neuronal destruction, particularly in cholinergic neurons. Drugs that inhibit the degradation of acetylcholine within synapses are the mainstay of therapy.
American Family Physician June 1, 2003 Motsinger et al.	Use of Atypical Antipsychotic Drugs in Patients with Dementia Increasingly, atypical antipsychotic drugs are prescribed for elderly patients with symptoms of psychosis and behavioral disturbances. To minimize side effects, these medications should be started at low dosages that are increased incrementally.
Fast Company Christina Farr	AHA, Alphabet Set Aside $75 Million To Cure Coronary Heart Disease The American Heart Association, Verily (the company formerly known as Google Life Sciences), and European pharmaceutical giant AstraZeneca are investing the funds over a five-year period.
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
AskMen.com Joshua Levine	Selling Your Body To Science Have you ever thought about the number of voluntary patients who basically sell their bodies to clinical trials in the name of science? Well, the number is staggering and it can reach well into the thousands. The main reason being the large paycheck that comes with the job.
American Family Physician November 1, 2005 Snyder & Pendergraph	Detection and Evaluation of Chronic Kidney Disease Early treatment of chronic kidney disease and its complications may delay or prevent the development of end-stage renal disease. Consequently, detection of chronic kidney disease should be a priority for family physicians.
The Motley Fool June 17, 2008 Brian Orelli	Change a Label, Change the Game For Teva Pharmaceutical, swapping the label on its Parkinson's drug, Azilect, could add hundreds of millions of dollars in sales per year.
The Motley Fool October 13, 2006 Rich Duprey	NICE Is Just Dumb The British health agency prohibits the use of certain Alzheimer's treatments because of cost.